Close Menu

Editor's Pick

A SNP in the pan-SARS E gene has not affected patient results, but has raised concerns about the overall unavailability of commercial primer and probe information.

Two companies offering droplet-based single-cell RNA sequencing sample prep, 10x Genomics and 1Cellbio, have launched dual-indexed library preparation products.

Belgium's OncoDNA believes that IntegraGen's bioinformatics platform will help it manage more cancer patient data and quickly generate patient-specific treatment reports for clinicians.

In the next round of the eMERGE program, NIH is supporting development of methodologies for integrating genotypic and phenotypic risk scoring into clinical care. 

The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.

The company hopes to improve its Dragen analysis platform with data compression technology from Enancio and data management capabilities from BlueBee.

The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.

Bruker's system has seen strong uptake among proteomics researchers, but its ability to generate large amounts of complex data has led to analysis challenges.

Users will be able to sequence over 20,000 samples simultaneously with the updated panel, which the firm expects to offer sometime in the third quarter for research use only. 

A handful of researchers and companies are hoping to finally bring the paper-based molecular diagnostic space to fruition.

Pages

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.